BCPCNasdaqChemicals & Allied ProductsFiscal year ends December 31
BALCHEM CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$170.42−0.31 (-0.18%)
Close on Oct 19, 2026
- Market cap
- $5.49B
- P/E (TTM)
- 33.5
- Dividend yield
- 0.56%
BALCHEM CORP revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Human Nutrition and Health | $659.39M | $600.26M | $550.75M | $527.13M | $442.73M | $400.33M | $347.43M | $341.24M | $315.80M | $297.13M | 63.6% | +9.9% |
| Animal Nutrition and Health | $230.85M | $214.71M | $238.33M | $262.30M | $226.78M | $192.19M | $177.56M | $175.69M | $157.69M | $161.12M | 22.3% | +7.5% |
| Specialty Products | $140.98M | $132.75M | $125.97M | $131.44M | $117.02M | $103.57M | $92.26M | $75.81M | $73.36M | $70.13M | 13.6% | +6.2% |
| Other and Unallocated | – | – | – | – | – | – | $26.46M | $50.94M | $47.95M | $24.83M | – | – |
| Human Nutrition & Health [Member] | – | – | – | – | – | – | – | – | – | $297.13M | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Human Nutrition and Health | $153.91M | $135.96M | $102.42M | $82.13M | $76.03M | $61.40M | $48.43M | – | – | – | +13.2% |
| Specialty Products | $42.90M | $39.91M | $34.58M | $32.79M | $30.02M | $26.80M | $28.51M | – | – | – | +7.5% |
| Animal Nutrition and Health | $18.69M | $14.01M | $27.58M | $36.06M | $26.18M | $29.98M | $25.87M | – | – | – | +33.4% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Sales Revenue | $1.04B | $951.95M | $919.95M | $939.17M | $794.52M | $666.19M | $609.74M | $607.88M | $564.03M | $505.17M | 99.8% | +8.8% |
| Royalty Revenue | $1.89M | $1.74M | $2.49M | $3.19M | $4.51M | $4.29M | $4.36M | $4.49M | $4.64M | $3.40M | 0.2% | +8.8% |
| Consignment | – | – | – | $4.23M | $4.44M | $2.94M | $2.30M | $2.44M | $2.33M | $2.17M | – | – |
| Bill and Hold | – | – | – | $0 | $0 | $1.16M | $3.22M | $4.61M | $4.09M | $3.06M | – | – |
| Co-manufacturing | – | – | – | $40.62M | $27.99M | $29.06M | $24.09M | $24.26M | $19.70M | $39.40M | – | – |
| Product Sales Revenue | – | – | – | $939.17M | $794.52M | $699.35M | $639.35M | $639.19M | $590.15M | $549.80M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $759.45M | $723.30M | $689.60M | $682.24M | $584.66M | $516.35M | $475.03M | $482.69M | $460.60M | $420.82M | 73.2% | +5.0% |
| Foreign Countries | $277.71M | $230.38M | $232.84M | $260.12M | $214.36M | $187.30M | $168.67M | $160.99M | $134.19M | $132.38M | 26.8% | +20.5% |
From the segment and revenue-disaggregation notes of Balchem's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.